knowledge -WSS

knowledge

author：leisure time 2025-09-30 00:49:04 - browse：222

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： The stability of $0 premiums in Medicare Advantage

explore

focus

WSS

What we owe ALS patients — and why one company fell short

Research misconduct: Proposed new rules face resistance

AI generated plenty of interest at JPM but not a lot of trust

Some top drug companies are starting to take action on climate

Flu, Covid vaccination rates decline, new survey data show

2023 Nobel Prize in Medicine goes to Karikó and Weissman

entertainment

knowledge

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Research misconduct: Proposed new rules face resistance

Sports medicine is finally prioritizing gender equality

Prior authorization will have to move faster under new Biden rule

Medical records are filled with copy

RSV injection headlines need to be accurate for good uptake

Affirmative action in medical school literally saved lives

What will Novo Nordisk's VC do with its influx of cash?

Cancer drug shortages should be causing more outrage

eGenesis tests gene

explore

Congress extends some pandemic preparedness programs

WHO recommends second malaria vaccine

Readout Newsletter: Merck, J&J, and long Covid

eGenesis tests gene

NIH director takes cautious approach to Biden drug pricing priority

With Roe v Wade overturned, abortion providers work to adapt

explore

explore

focus

focus